US Firm Forms Adisory Board to Help Develop Honey Wound Dressing

Derma Sciences Appoints Clinical Advisory Board
Lab Business Week, 4/22/2007

Derma Sciences, Inc. (OTCBB: DSCI), a manufacturer and full line supplier of wound and skin care products, announced the formation of a Clinical Advisory Board to help guide the Company's clinical development strategy for its Active Manuka Honey (API-MED(TM)) line of dressings currently under review for 510K clearance, and its MOBILITY-1(TM) Intermittent Pneumatic Compression (IPC) Therapy device.

Comprised of US key opinion leaders in wound care, burn care, dermatology and vascular diseases and surgery, the Clinical Advisory Board will play an important role in guiding the upcoming launch of the Active Manuka Honey based product which, if approved, will be the first dressing with honey approved for medical use in the US. The Company believes Active Manuka Honey could represent a great improvement over current topical antimicrobials, including ionic silver…

"With the planned launch of our Active Manuka Honey based wound care products and the recently announced licensing agreement with the manufacturers of our MOBILITY-1(TM) branded product line, we have in place an aggressive plan to help drive market acceptance of these truly unique approaches to active wound care and the treatment of vascular diseases," said Edward J. Quilty, Chairman, President and CEO. “ The market for active wound care is the fastest growing segment of the $4 billion wound care market..."